Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04650555 · ClinicalTrials.gov registry record · Phase 1
BIO 300 Oral Powder Safety and Pharmacokinetics
A Phase 1 study of Acute Radiation Syndrome, sponsored by Humanetics Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT04650555: Completed Phase 1 study of Acute Radiation Syndrome, sponsored by Humanetics Corporation.
NCT04650555 is a Phase 1 study of Acute Radiation Syndrome that has completed, run by Humanetics Corporation. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04650555, a Phase 1 study of Acute Radiation Syndrome, has completed, sponsored by Humanetics Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given daily for 6 consecutive days.
Primary Outcome
Evaluate the safety of single and multiple dose BIO 300 Oral Powder administration
Conditions Studied
Interventions
- DRUG BIO 300 Oral Powder
Study Locations (1)
Minnesota
- Nucleus Network, Ltd (Formally Prism Research, LLC) - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2021-07-06 |
| Phase | Phase 1 |
What the finished NCT04650555 record still lists
NCT04650555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Acute Radiation Syndrome appearing as the primary indexed condition, and to 1 intervention - of which BIO 300 Oral Powder is the first listed.
NCT04650555 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04650555 about?
NCT04650555 is a clinical study titled "BIO 300 Oral Powder Safety and Pharmacokinetics". Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given...
What is the current status of trial NCT04650555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2020-12-08. Estimated completion is 2021-07-06.
What conditions does trial NCT04650555 study?
This clinical trial studies the following conditions: Acute Radiation Syndrome.
What interventions are being tested in trial NCT04650555?
The interventions under investigation include: BIO 300 Oral Powder (DRUG).
Who is sponsoring clinical trial NCT04650555?
This trial is sponsored by Humanetics Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04650555 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04650555's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI